uniQure’s AMT‑130 gene therapy receives FDA priority review with a May 2027 decision target
uniQure announced that the FDA accepted its biologics license application for AMT‑130, its Huntington’s disease gene therapy, and placed it in priority review with a PDUFA date of May 1, 2027. The company reported Q3 2026 revenue of $5.2 million, a net loss of $61.2 million, and said it holds $768.4 million in cash and investments, which it expects will fund operations into 2030. Management outlined a confirmatory study of roughly 200 patients and a planned U.S. launch in mid‑2027.
Why it matters
The priority‑review status shortens the regulatory timeline, allowing a potential U.S. launch as early as mid‑2027 (the company says). The cash position gives the firm runway to commercialize AMT‑130 and advance its pipeline through 2030, reducing financing risk for investors.
Key facts
- 1The FDA accepted uniQure’s biologics license application for AMT‑130 and granted priority review with a PDUFA date of May 1, 2027. seekingalpha.com
- 2Q3 2026 revenue was $5.2 million, up from $3.7 million in the prior year period. finance.yahoo.com
- 3Net loss for the quarter was $61.2 million, or $0.88 per share, improving from a $80.5 million loss a year earlier. fool.com
- 4Cash and investment securities totaled $768.4 million as of September 30, 2026. fool.com
- 5The confirmatory study will enroll approximately 200 patients in a 2:1 ratio of high‑dose AMT‑130 to standard of care. fool.com
- 6Management expects the cash position to fund operations into 2030. tradingview.com
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.